35% objective response rate (ORR) in second-line colorectal cancer (CRC) patients treated with sirexatamab (DKN-01) plus bevacizumab and chemotherapy, compared to 23% ORR in the control arm DKK1 levels highly correlated with clinical activity in CRC population ORR benefit with sirexatamab observed across multiple potential Phase 3 CRC populations Preparations will begin for a registrational Phase 3 study in second-line CRC patients DisTinGuish Part C study in gastric cancer demonstrates activity in biomarker populations, but not the signal necessary to advance into Phase 3 Leap to host a conference call to present clinical data today, January 28, 2025, at 8:00 a.m. ...

JetBlue (NASDAQ: JBLU) today announced it will be ‘kicking off’ limited time nonstop flights to bring hundreds more sports fans to the big game. The airline will add flights in Newark and from its home at New York’s JFK Airport to New Orleans, giving football fans in JetBlue cities the perfect play and more options to cheer on their team and get in on the action. Flights are now available for booking on jetblue.com.

WENZHOU, China, Jan. 28, 2025 /PRNewswire/ -- ZK International Group Co., Ltd. (NASDAQ: ZKIN) ("ZK International" or the "Company"), a leader in high-performance stainless steel and carbon steel pipe solutions, is excited to invite its shareholders and interested parties to a special conference call to discuss the Company's latest achievements, major upcoming news, and strategic growth plans for the future.

This financing is expected to support filing of New Drug Applications for NRX-100 (ketamine) and NRX-101, and to support launch of HOPE TherapeuticsInvestment consists of $3.5 million in above the market equity and $5.4 million in Senior Secured Notes; expected to fund current operations into 2026WILMINGTON, Del., Jan. 28, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) ("NRx", "NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it has entered into a binding agreement for a registered direct offering of its common stock with expected gross proceeds of $3.5 million (the "Financing") with certain institutional investors. The Company ...